Novartis receives approval in Japan for two innovative therapies, Gilenya® in MS and Ilaris® in CAPS
27 September 2011 | By Novartis
Novartis has received regulatory approval in Japan for once-daily Gilenya (fingolimod)...
List view / Grid view
News
New data shows potential of respiratory portfolio to help COPD patients maintain active and productive lives
27 September 2011 | By Novartis
Novartis has presented new Phase III data at the ERS congress...
Your successful start in microencapsulation
26 September 2011 | By Buchi
The Encapsulator B-390 & B-395 Pro, are designed for the immobilization of enzymes, drugs...
Boehringer Ingelheim expands its business with Biosimilars
26 September 2011 | By Boehringer Ingelheim
Boehringer Ingelheim will establish a new separate business for the development and commercialization of own biosimilars...
Wyatt Technology’s FFF-MALS Provides Efficient Liposome Characterization
26 September 2011 | By The Scott Partnership
Field Flow Fractionation (FFF) technology announced...
ALIMTA helped keep most common form of lung cancer at bay in elderly patients
26 September 2011 | By Eli Lilly and Company
New data from PARAMOUNT study shows benefit in this hard-to-treat population...
Afinitor® helps women with advanced breast cancer live longer without their disease progressing
26 September 2011 | By Novartis
Afinitor® more than doubled the time women lived without tumor growth...
ALIMTA receives positive opinion from CHMP
26 September 2011 | By Eli Lilly and Company
CHMP has issued a positive opinion for the use of ALIMTA® as continuation maintenance therapy for deadly form of lung cancer...
AstraZeneca announces first approval of FASLODEX™ (fulvestrant) in Japan
26 September 2011 | By AstraZeneca
AstraZeneca announced that FASLODEX™ (fulvestrant) has received regulatory approval...
Roche’s investigational medicine T-DM1 shows improvement in progression-free survival compared to standard of care in HER2-positive metastatic breast cancer
25 September 2011 | By Roche
Phase II study TDM4450g results announced...
KOMBOGLYZE™ receives positive CHMP opinion in the European Union for the treatment of type 2 diabetes
23 September 2011 | By AstraZeneca
KOMBOGLYZE™ receives a positive opinion from CHMP...
Novartis gains positive CHMP opinion for Rasitrio®
23 September 2011 | By Novartis
The CHMP adopted a positive opinion for Rasitrio® for the treatment of high blood pressure...
Novartis drug Afinitor® effective in patients with non-cancerous kidney tumors associated with TSC in Phase III trial
23 September 2011 | By Novartis
A Phase III study of Afinitor® (everolimus) tablets* met its primary endpoint of best overall angiomyolipoma response rate...
European CHMP adopts positive opinion for Eviplera(R)
23 September 2011 | By Gilead Sciences, Inc.
CHMP, has adopted a positive opinion on the company's Marketing Authorisation Application for the once-daily single-tablet regimen, Eviplera(R)...
Positive opinion on the usage of Levemir® (insulin detemir) as add-on therapy to Victoza® (liraglutide) in people with type 2 diabetes
23 September 2011 | By Novo Nordisk
CHMP has adopted a positive opinion on the usage of Novo Nordisk’s basal insulin analogue, Levemir®...
